Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MNPR 
Monopar Therapeutics Inc (MNPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MNPR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $82
1 Year Target Price $82
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 328.79% | Avg. Invested days 49 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 336.20M USD | Price to earnings Ratio - | 1Y Target Price 82 |
Price to earnings Ratio - | 1Y Target Price 82 | ||
Volume (30-day avg) 5 | Beta 1.22 | 52 Weeks Range 3.90 - 58.94 | Updated Date 09/16/2025 |
52 Weeks Range 3.90 - 58.94 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.12% | Return on Equity (TTM) -59.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 250515437 | Price to Sales(TTM) - |
Enterprise Value 250515437 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 6169960 | Shares Floating 2938197 |
Shares Outstanding 6169960 | Shares Floating 2938197 | ||
Percent Insiders 34.25 | Percent Institutions 51.83 |
Upturn AI SWOT
Monopar Therapeutics Inc
Company Overview
History and Background
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics to treat serious diseases. Founded in 2014, the company has focused on developing treatments for cancer and infectious diseases.
Core Business Areas
- Oncology: Development of cancer therapies, particularly focused on treatments that address unmet needs in oncology.
- Infectious Diseases: Development of treatments for infectious diseases.
Leadership and Structure
Chandler D. Robinson serves as Chief Executive Officer. The company has a typical corporate structure with departments for research & development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- Validive (Clonidine Mucoadhesive Buccal Tablet): Validive is intended for the prevention of severe oral mucositis induced by chemoradiation therapy for head and neck cancer. Monopar acquired the rights to develop Validive, which has completed Phase 3 trials. Market share is not currently applicable due to pre-commercialization phase. Competitors: Amgen (KYPROLIS for multiple myeloma).
- Camsirubicin: Camsirubicin is a pre-clinical stage investigational compound being developed to reduce cancer chemotherapy induced neutropenia. Competitors: Spectrum Pharmaceuticals (ROLONTIS), Amgen (Neulasta).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with companies focused on developing new therapies for a wide range of diseases. It requires significant investment and is subject to regulatory oversight.
Positioning
Monopar is positioned as a clinical-stage biopharmaceutical company focused on developing therapies in areas with unmet needs. Its competitive advantages include its proprietary compounds and focus on innovative treatments.
Total Addressable Market (TAM)
The TAM for cancer and infectious disease therapeutics is substantial, estimated to be hundreds of billions of dollars globally. Monopar is targeting niche segments within these larger markets.
Upturn SWOT Analysis
Strengths
- Proprietary compounds in development
- Experienced management team
- Focus on unmet medical needs
- Potential for orphan drug designation for some products
Weaknesses
- Limited financial resources
- Clinical trial risks and uncertainties
- Dependence on regulatory approvals
- Small market capitalization
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Acquisition of complementary assets
Threats
- Competition from larger pharmaceutical companies
- Regulatory setbacks
- Failure to obtain funding
- Patent challenges
Competitors and Market Share
Key Competitors
- AMGN
- TEVA
- PFE
Competitive Landscape
Monopar faces significant competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its innovative therapies and niche market focus.
Growth Trajectory and Initiatives
Historical Growth: Monopar's historical growth is characterized by the progression of its clinical programs. Stock value has fluctuated.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates are uncertain and vary widely.
Recent Initiatives: Advancement of Validive and Camsirubicin through clinical trials, strategic collaborations for funding and development.
Summary
Monopar Therapeutics is a clinical-stage biopharmaceutical company with potential in its pipeline, but carries high risk. Its success hinges on clinical trial outcomes and regulatory approvals. Limited financial resources and competition pose challenges. Strategic partnerships and successful trials are critical for its future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Sources
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monopar Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmette, IL, United States | ||
IPO Launch date 2019-12-19 | Co-Founder, CEO, President & Director Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.monopartx.com |
Full time employees 14 | Website https://www.monopartx.com | ||
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.